Cortechs.ai
Cortechs.ai develops AI-powered quantitative neuroimaging and prostate imaging software for radiologists, neurologists, and oncologists. Its NeuroQuant and OnQ Prostate platforms deliver automated brain and prostate MRI analysis to 1,400+ hospitals and imaging centers across 44 countries via subscription licensing and OEM integrations.
- Company typePrivate
- Founded2002
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Cortechs.ai does
Cortechs.ai, founded in 1996 as Cortechs Labs and incorporated in 2002 in San Diego, develops AI-powered quantitative imaging software for radiologists, neurologists, and oncologists. Its flagship platform, NeuroQuant, performs automated brain segmentation and volumetric analysis across MRI, CT, and PET scans using a proprietary Dynamic Atlas technology that supports ages 3-100. Specialized add-on modules address multiple sclerosis (NeuroQuant MS), brain tumors (NeuroQuant Brain Tumor), ARIA monitoring for anti-amyloid Alzheimer's therapies (NeuroQuant Lesion Surveillance), automated head CT analysis (NeuroQuant CT, acquired from ZepMed in October 2025), and PET tracer quantification (NeuroQuant PET, FDA 510(k)-pending). The company's second core product line, OnQ Prostate, applies a patented Restriction Spectrum Imaging (RSI) diffusion MRI method to improve detection and localization of clinically significant prostate cancer.
The company generates revenue through quote-based annual subscription licensing of its software to hospitals and imaging centers, with products compatible with CPT reimbursement codes (0865T, 0866T for brain MRI and 0649T for prostate MRI). Its go-to-market combines direct enterprise sales, embedded OEM integrations with the three dominant imaging vendors (Philips Smart Reading, Siemens Healthineers Digital Marketplace, and Microsoft PowerScribe One on Azure), and regional distribution partners across Benelux, India, Italy, Turkey, the Middle East, Peru, South Korea, and Canada. With over 1,400 hospital and imaging center customers across 44 countries, 2M+ brains scanned, and multiple FDA 510(k) clearances, Cortechs.ai operates a horizontal segmentation strategy spanning neurology, prostate oncology, neuro-oncology, and MS care. The company is venture-backed, having closed an oversubscribed Series C led by VILAS Ventures with participation from Genting Berhad in November 2024, and maintains SOC 2 Type 2 certification for its cloud platform.
Cortechs.ai firmographics
Firmographics- Name
- Cortechs.ai
- Legal name
- Cortechs.ai
- Website
- https://cortechs.ai
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cortechs.ai develops AI-powered quantitative neuroimaging and prostate imaging software for radiologists, neurologists, and oncologists. Its NeuroQuant and OnQ Prostate platforms deliver automated brain and prostate MRI analysis to 1,400+ hospitals and imaging centers across 44 countries via subscription licensing and OEM integrations.
- Ownership category
- akta.pro rank
Cortechs.ai industry classification
Industry- Product category
- AI-Powered Radiology Imaging Software
- NAICS
- Software Publishers (5132), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Medical Imaging AI (HDAAAEAH), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
Keywords
Where Cortechs.ai is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Cortechs.ai business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- Software Licensing and Subscriptions: The company generates revenue through software licensing of its NeuroQuant and OnQ Prostate platforms to hospitals and imaging centers. Products are compatible with CPT codes 0865T and 0866T for AI-assisted quantitative brain MRI analysis, supporting reimbursement.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise licensing for hospitals and imaging centers |
Go-to-market motion1 record
Distribution channels8 records
Marketing channels4 records
Cortechs.ai product offering
Product offeringCore offering
Cortechs.ai develops and sells cloud-based AI medical imaging software that performs automated brain segmentation, volumetric analysis, and quantitative measurements from MRI, CT, and PET scans. Its NeuroQuant platform supports neurological and oncological assessment (Alzheimer's, MS, epilepsy, TBI, brain tumors, ARIA monitoring), and OnQ Prostate adds FDA-cleared diffusion MRI analysis for prostate cancer detection. The software is licensed to hospitals, imaging centers, radiologists, neurologists, and oncologists and integrates into PACS and OEM imaging systems from Philips, Siemens, and GE.
Product overview
Cortechs.ai offers a cloud-based AI-powered medical imaging platform primarily focused on neuroimaging and oncology. The core products are NeuroQuant (brain segmentation and volumetric analysis) and OnQ Prostate (prostate MRI with Restriction Spectrum Imaging). NeuroQuant serves as the primary platform with specialized add-on modules including NeuroQuant MS (multiple sclerosis lesion tracking), NeuroQuant Brain Tumor (glioma, metastasis, and meningioma segmentation), NeuroQuant Lesion Surveillance (ARIA monitoring for anti-amyloid therapy), NeuroQuant CT (automated head CT analysis acquired from ZepMed), and NeuroQuant PET (PET tracer quantification, FDA 510(k)-pending). All NeuroQuant modules share the Dynamic Atlas technology for consistent age-accurate segmentation. The company operates on a platform-plus-modules architecture where the core NeuroQuant engine supports specialized clinical applications, while OnQ Prostate represents a distinct product line focused on prostate cancer detection using RSI technology.
Differentiator
Problem solved
Functional benefit
Brands
- NeuroQuant: Best-in-class brain segmentation and volumetric analysis AI software for neurodegenerative disease detection and monitoring.
- NeuroQuant MS
- NeuroQuant Brain Tumor
- NeuroQuant Lesion Surveillance
- NeuroQuant CT
- NeuroQuant PET
- OnQ Prostate
- Dynamic Atlas
Products and services
- NeuroQuant Best-in-class cloud-based AI software for brain segmentation and volumetric analysis. Segments, quantifies, and compares brain structure volumes for neurodegenerative disease assessment using Dynamic Atlas technology covering ages 3-100. Includes multiple report types (Dementia, MVID, TBA, MSA, Seizure, Pediatrics, Custom, General) and supports Alzheimer's, MS, epilepsy, TBI, and ARIA. Targeted at radiologists, neurologists, and imaging centers.
- NeuroQuant MS Specialized module for multiple sclerosis that automatically labels and visualizes MS lesions with color-coded segmentation. Provides longitudinal tracking of new, stable, shrinking, and enlarging lesions and includes a FLAIR Lesion and Atrophy Report with lesion burden and count metrics for treatment planning. For neurologists and radiology departments managing MS patients.
- NeuroQuant Brain Tumor FDA-cleared AI software for brain tumor analysis assisting radiologists, oncologists, and neurosurgeons. Provides automated volumetric segmentation and tracking of gliomas (high-grade and low-grade), brain metastases, and meningiomas in pre- and post-operative studies. Generates RT STRUCT outputs for radiation oncology and surgical planning.
- NeuroQuant Lesion Surveillance FDA-cleared automated solution for quantification, visualization, and longitudinal tracking of brain lesions. First clinically validated solution identifying cerebral microbleeds and superficial siderosis on T2*GRE and SWI scans, combined with FLAIR lesion quantification. Supports ARIA monitoring for patients on anti-amyloid Alzheimer's therapies with FLAIR and GRE surveillance reports.
- NeuroQuant CT FDA-cleared automated post-processing software for head CT scans. Registers CT images to anatomical atlas along the AC-PC plane, quantifies lateral ventricle volume, calculates midline shift index, and generates subtraction maps by co-registering current and prior exams. Acquired from ZepMed (formerly NeuroAlign CT). For emergency departments, radiology, and neurology departments performing head CT.
- NeuroQuant PET Rapid automated regional tracer quantification for brain PET images. Provides fully automated quantification of Amyloid, Tau, and FDG PET data with Centiloid quantification for comparison across tracers and time. FDA 510(k)-pending (Research Use Only). Supports PET-MRI, PET-CT, or PET-only workflows. Targets nuclear medicine and dementia-imaging programs.
- OnQ Prostate FDA-cleared prostate MRI software using patented Restriction Spectrum Imaging (RSI) diffusion MRI method. Improves detection, in vivo characterization, and localization of clinically significant prostate cancer. Generates Restricted Signal Maps and Color Fusion Maps for enhanced PI-RADS scoring, biopsy targeting, and treatment planning. For urology practices, radiology departments, and cancer centers.
Quantifiable outcome
- 19% improvement in radiologist certainty when determining a change in ventricular volume
- +3 more outcomes
Companies that use Cortechs.ai
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles1 record
Cortechs.ai technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability5 records
Feature6 records
Cortechs.ai partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and regional.
- MicrosoftcoreStrategic collaboration to integrate AI-powered quantitative imaging biomarkers into clinical radiology workflows through Microsoft's PowerScribe One platform using Azure cloud infrastructure. Embeds NeuroQuant and OnQ Prostate applications into Microsoft's radiology ecosystem.
- ARJ MedicalregionalPartnership to advance AI-driven neuro and prostate imaging in the Middle East region.
- Siemens HealthineerscorePartnership to integrate NeuroQuant Lesion Surveillance into Siemens Healthineers Digital Marketplace, enabling clinicians to access automated lesion segmentation, volumetric quantification, and longitudinal tracking within existing radiology workflows.
- PhilipscoreExtended partnership to integrate Cortechs.ai's AI-enabled neuroimaging analytics directly into Philips MR systems through the Smart Reading environment. Provides automated quantitative brain analysis for conditions like Alzheimer's disease, MS, and brain tumors via zero-click workflow.
- Strategic RadiologycoreExpanded partnership to advance imaging innovation across private practices. Alliance now includes Cortechs.ai's full suite of imaging solutions for private radiology practices.
- RMS Medical DevicesregionalDistribution partnership to expand access to AI-powered neuroimaging solutions in the Benelux region (Belgium, Netherlands, Luxembourg).
- deepccoreStrategic partnership to advance AI integration in radiology through deepc's platform capabilities.
- ALZ-NETcoreStrategic collaboration to improve Alzheimer's disease care through AI-driven imaging, specifically supporting ARIA monitoring for patients on anti-amyloid therapies.
- Kryptonite SolutionsregionalDistribution partnership to expand AI-driven neuroimaging access in India.
- Medical HorizonsregionalDistribution partnership to expand presence in Italy, Turkey, and the Middle East.
- EDAP TMSregionalWorld's first OnQ Prostate-assisted Focal One robotic HIFU procedure at UCSF Prostate Cancer Center, demonstrating integration with EDAP's robotic HIFU technology.
- Mermaid Beach RadiologyregionalPartnership to bring precision AI imaging solutions to MRI and CT services.
- Ascend ImagingregionalStrategic partnership to expand access to cutting-edge radiology solutions.
Scale indicators9 records
Recent moves10 records
Expansion highlights8 records
Cortechs.ai competitors and assessment
Company assessmentDirect peers
- Viz.ai: Viz.ai builds radiology AI workflow and care-coordination software, primarily known for neurovascular triage but expanding across enterprise imaging; it competes with Cortechs.ai for neuro AI placement within hospital systems.
- icometrix: icometrix provides AI-based brain MRI quantification (e.g., icobrain) for multiple sclerosis, dementia, and similar neurodegenerative use cases, making it a direct, like-for-like competitor to Cortechs.ai's NeuroQuant product line in quantitative neuroimaging.
- Aidoc: Aidoc is a leading clinical AI platform offering radiology AI modules across multiple body parts and triage use cases, competing for the same hospital and imaging center AI budgets as Cortechs.ai, although with a broader body-part coverage.
- MIM Software: MIM Software provides medical imaging post-processing and AI-driven quantification across modalities including brain MRI and prostate, sitting in the same clinical and enterprise imaging workflow slots as Cortechs.ai.
- RapidAI: RapidAI offers AI neuroimaging products (stroke, aneurysm, and now expanded modules), overlapping with Cortechs.ai's NeuroQuant brain volumetric and lesion surveillance offerings for neurology and neuroradiology.
- Quibim: Quibim provides AI-powered medical image analysis across MRI and CT, including quantitative brain imaging biomarkers for neurodegenerative disease, closely mirroring Cortechs.ai's quantitative neuroimaging value proposition.
Emerging players
- Annalise.ai: Annalise.ai offers a comprehensive radiology AI suite covering chest, brain, and other body parts; it competes for the same multi-modality imaging AI budgets that hospitals weigh against Cortechs.ai's brain and prostate offerings.
- Perspectum: Perspectum develops quantitative imaging biomarkers, with strong presence in liver and brain MR analysis, overlapping with Cortechs.ai's volumetric brain quantification for chronic disease management.
- Blackford Analysis: Blackford operates an AI marketplace and integration platform for radiology algorithms, including third-party brain and prostate AI apps; it intersects with Cortechs.ai at the distribution/platform layer rather than as a direct algorithm competitor.
- Subtle Medical: Subtle Medical focuses on AI-based image enhancement and acceleration for MRI and PET, sitting adjacent to Cortechs.ai's quantitative analysis products and competing for the same modality-based AI slots in radiology departments.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Cortechs.ai social profiles
Digital presenceCortechs.ai compliance and trust
Trust signalCompliance1 record
Cortechs.ai financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cortechs.ai leadership team
Management profileNumber of profiles
Profiles14 records
Cortechs.ai funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cortechs.ai M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cortechs.ai
What does Cortechs.ai do?
Cortechs.ai develops and sells cloud-based AI medical imaging software that performs automated brain segmentation, volumetric analysis, and quantitative measurements from MRI, CT, and PET scans. Its NeuroQuant platform supports neurological and oncological assessment (Alzheimer's, MS, epilepsy, TBI, brain tumors, ARIA monitoring), and OnQ Prostate adds FDA-cleared diffusion MRI analysis for prostate cancer detection. The software is licensed to hospitals, imaging centers, radiologists, neurologists, and oncologists and integrates into PACS and OEM imaging systems from Philips, Siemens, and GE.
Is Cortechs.ai a public or private company?
Cortechs.ai is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cortechs.ai founded?
Cortechs.ai was founded in 2002. It employs 51 to 100 people.
Where is Cortechs.ai based?
Cortechs.ai is headquartered in San Diego, United States, in the North America region.
How does Cortechs.ai make money?
One revenue line is on record: software Licensing and Subscriptions.
Who are Cortechs.ai's main competitors?
Direct peers on record are Viz.ai, icometrix, Aidoc, MIM Software, RapidAI and Quibim. Emerging players are Annalise.ai, Perspectum, Blackford Analysis and Subtle Medical.
Does Cortechs.ai have an API?
No public API is recorded for Cortechs.ai.
What industry is Cortechs.ai in?
Cortechs.ai's product category is AI-Powered Radiology Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 5132 and its SIC code is 7372.